Skip to main content

Table 1 Demographics of study population

From: Superior diagnostic performance of perfusion-cardiovascular magnetic resonance versus SPECT to detect coronary artery disease: The secondary endpoints of the multicenter multivendor MR-IMPACT II (Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary Artery Disease Trial)

 

n (%)

Patients enrolled and CM administered:1

515

Male sex

377 (73.2)

Age (mean±SD)

60±10.3 years

Body mass index (mean±SD)

28.2±4.3 kg/m2

Risk factors:

 Hypertension

358 (69.5)

 Hypercholesterolemia

354 (68.8)

 Diabetes

92 (17.8)

History of heart failure

106 (20.6)

Myocardial infarction

139 (27.0)

Percutaneous coronary intervention (PCI)

170 (33.0)

Angina pectoris

414 (80.4)

 CCS I

87 (16.9)

 CCS II

227 (44.1)

 CCS III

46 (8.9)

 CCS IV

21 (4.1)

Patients with all 3 test data sets complete (efficacy population):

n 465

Coronary artery disease

227 (48.8)

 Left main

14 (3.0)

 LAD

134 (28.8)

 LCX

104 (22.4)

 RCA

112 (24.1)

Multivessel disease

113 (24.3)

Myocardial infarction

129 (27.7)

Medication:

 Any drugs

496 (96.4)

 Beta-blockers

367 (71.3)

 Lipid lowering

354 (68.8)

 Angiotensin-converting enzyme inhibitors

306 (59.4)

 Diuretics

131 (25.5)

 Calcium channel blockers

99 (19.2)

 Antithrombotic

425 (82.6)

MR – not evaluable

26 (5.6)

SPECT – not evaluable

17 (3.7)

  1. CCS: Canadian Cardiovascular Society; LAD: left anterior descending coronary artery; LCX: left circumflex coronary artery; RCA: right coronary artery.
  2. 1 Eighteen patients were recruited but did not receive MR contrast medium, for reasons, see Flow chart in Figure 1.